The use of antioxidant compounds in the treatment of first psychotic episode: Highlights from preclinical studies

CNS Neuroscience & Therapeutics
Stefania Schiavone, Luigia Trabace

Abstract

Recent evidence highlighted a pathogenetic link between redox dysregulation and the early stages of psychosis. Indeed, an increasing number of studies have pointed toward an association between oxidative stress, both at central and peripheral levels, and first psychotic episode. Moreover, basal low antioxidant capacity has been shown to directly correlate with cognitive impairment in the early onset of psychosis. In this context, the possibility to use antioxidant compounds in first psychotic episode, especially as supplementation to antipsychotic therapy, has become the focus of numerous investigations on rodents with the aim to translate data on the possible effects of antioxidant therapies to large populations of patients, with a diagnosis of the first psychotic episode. In this review, we will discuss studies, published from January 1st, 2007 to July 31st, 2017, investigating the effects of antioxidant compounds on neuropathological alterations observed in different rodent models characterized by a cluster of psychotic-like symptoms reminiscent of what observed in human first psychotic episode. A final focus on the effective possibility to directly translate data obtained on rodents to humans will be also provided.

References

Jan 1, 1984·Annals of the New York Academy of Sciences·W Cammer
Feb 20, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Olivier BaudPaul A Rosenberg
Oct 23, 2009·Acta Neuropathologica·Monika Bradl, Hans Lassmann
Aug 6, 2010·Neurobiology of Aging·Petroula ProitsiJohn F Powell
Oct 7, 2010·The International Journal of Neuropsychopharmacology·Erica ZamberlettiDaniela Parolaro
Oct 19, 2010·Journal of Psychopharmacology·Rodrigo S SestitoMaria L N M Rosa
Dec 4, 2010·Antioxidants & Redox Signaling·Jeffrey K Yao, Matcheri S Keshavan
Feb 12, 2011·Current Topics in Behavioral Neurosciences·Susan B Powell
Mar 8, 2011·Current Opinion in Genetics & Development·Roberta Rasetti, Daniel R Weinberger
Jul 1, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David-Marian OtteAndreas Zimmer
Jan 17, 2012·Nature Neuroscience·Shinji MiyataHiroshi Kitagawa
Apr 11, 2012·Neuroscience and Biobehavioral Reviews·Meryem Alamy, Wail A Bengelloun
Jul 6, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Marine BeurdeleyAlain Prochiantz
Jul 27, 2012·Translational Psychiatry·Stefania SchiavoneK-H Krause
Sep 11, 2012·Neuron·Julia J HarrisDavid Attwell
Jan 10, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Fabio SambataroDaniel R Weinberger
Jan 17, 2013·Antioxidants & Redox Signaling·Marilena ColaiannaLuigia Trabace
Jan 18, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Terrell HollowayJavier González-Maeso
Jan 23, 2013·Neuropathology and Applied Neurobiology·G C DeLucaG C Ebers
Feb 14, 2013·Journal of Neuroscience Research·Martin A SantiniJens D Mikkelsen
May 15, 2013·Proceedings of the National Academy of Sciences of the United States of America·J H CabungcalKim Q Do
Apr 2, 2014·Nutrition Reviews·Elizabeth L Prado, Kathryn G Dewey
Jun 5, 2014·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Oliver KannAndreas Draguhn
Sep 13, 2014·Current Behavioral Neuroscience Reports·Alexandra D ForrestSteven J Siegel
Jun 15, 2015·Progress in Neuro-psychopharmacology & Biological Psychiatry·Jessica L AndrewsFrancesca Fernandez-Enright
Jul 15, 2015·Psychiatry and Clinical Neurosciences·Asli SarandolMelehat Dirican
Aug 12, 2015·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Stefan SmesnyG Paul Amminger
Sep 24, 2015·Anais Da Academia Brasileira De Ciências·Alexandra I ZugnoClarissa S Gama
Nov 13, 2015·Genes, Brain, and Behavior·S A Schoenrock, Lisa M Tarantino
Dec 15, 2015·Progress in Neuro-psychopharmacology & Biological Psychiatry·Gordana JevtićNataša D Petronijević
Mar 12, 2016·Behavioural Brain Research·Elizabeth E Manning, Maarten van den Buuse
Mar 21, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Stefania Schiavone, Luigia Trabace
Jul 30, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Alaa El-Sayed El-SisiEnass Yossef Osman
Oct 22, 2016·Expert Opinion on Drug Metabolism & Toxicology·Alessandro MinariniGian Maria Galeazzi
Jan 24, 2017·Behavioural Brain Research·Andrea GogosMaarten van den Buuse
Mar 1, 2017·Experimental Neurobiology·Suji HamHeh-In Im
Mar 18, 2017·International Journal of Molecular Sciences·Henry BarronRomina Mizrahi
Jun 1, 2017·NPJ Schizophrenia·Rehnuma IslamAmy J Ramsey

Related Concepts

Metazoa
Antioxidant Effect
Medicinal Plants Testing, Preclinical
Schizophreniform Disorders
Antipsychotic Effect
Antioxidants
Oxidation-Reduction
Psychotic Disorders
Rodent
Antipsychotic Agents

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse
Kara Simone BagotYifrah Kaminer
© 2021 Meta ULC. All rights reserved